Drug Price Trends for NDC 68094-0123

Average Pharmacy Cost for 68094-0123

Drug Name	NDC	Price/Unit ($)	Unit	Date

Best Wholesale Price for NDC 68094-0123

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
OXCARBAZEPINE 300MG/5ML SUSP	Golden State Medical Supply, Inc.	68094-0123-62	30X5ML	216.91		2023-06-16 - 2028-06-14	FSS

Eliquis (Apixaban) Patent Landscape and Market Projections

Last updated: February 19, 2026

What is the Current Patent Status of Eliquis (Apixaban)?

The primary patent for Eliquis (apixaban), U.S. Patent No. 7,399,768, covering methods of treating thrombotic disorders, is set to expire on July 20, 2026 [1]. However, Bristol Myers Squibb (BMS) and Pfizer, the drug's co-developers, have pursued a strategy of obtaining secondary patents to extend market exclusivity. These secondary patents cover various aspects of apixaban, including:

• Formulation Patents: These patents protect specific crystalline forms or formulations of apixaban, which can confer advantages such as improved stability or bioavailability. Examples include patents covering apixaban's amorphous solid dispersion [2].
• Method of Use Patents: These patents claim specific medical uses of apixaban, such as the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) or the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) [3].
• Polymorph Patents: Patents for specific crystalline forms (polymorphs) of apixaban, such as Form I and Form II, are critical. U.S. Patent No. 8,410,109, covering a specific crystalline form of apixaban, is a key example [4].
• Manufacturing Process Patents: Patents may also cover novel or improved processes for synthesizing apixaban, potentially offering manufacturing efficiencies or purity advantages [5].

The expiration dates of these secondary patents vary. For instance, U.S. Patent No. 8,410,109 is slated to expire in 2028, and other related patents extend into the early 2030s [4]. These extensions are a critical component of the drug's commercial lifecycle management.

What is the Market Size and Growth Trajectory of Eliquis?

Eliquis is a leading oral anticoagulant and has demonstrated substantial market growth since its launch.

• 2023 Net Sales: Bristol Myers Squibb reported net sales of Eliquis at $19.1 billion for the full year 2023 [6]. Pfizer's share also contributes significantly to the total revenue.
• Year-over-Year Growth: Eliquis achieved 10% operational growth in net sales in 2023 compared to 2022 [6]. This growth rate indicates sustained market demand.
• Market Penetration: Eliquis holds a significant share of the NOAC (novel oral anticoagulant) market, particularly in the NVAF indication, where it competes with rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Lixiana/Savaysa) [7].
• Projected Growth: The global market for anticoagulants is projected to grow due to an aging population, increasing prevalence of cardiovascular diseases, and broader adoption of NOACs over warfarin [8]. Analysts project the apixaban market to continue its upward trajectory, albeit at a potentially moderated pace post-patent expiry.

Table 1: Eliquis Net Sales Performance (USD Billions)

Year	Net Sales	Year-over-Year Growth (Operational)
2022	17.4	-
2023	19.1	10%

Source: Bristol Myers Squibb Financial Reports [6]

What are the Key Competitive Threats to Eliquis?

The primary competitive threat to Eliquis arises from the anticipated market entry of generic apixaban products following the expiration of its core patents.

• Generic Entry: Following the expiry of the main U.S. patent in July 2026, generic manufacturers are expected to file Abbreviated New Drug Applications (ANDAs) for apixaban. The success and timing of these filings depend on the legal challenges and patent litigation surrounding the secondary patents.
• Active Patent Litigation: BMS and Pfizer are actively defending their secondary patents. Litigation surrounding U.S. Patent Nos. 8,410,109 and 9,029,375, among others, is ongoing. The outcome of these legal battles will determine the extent and duration of continued market exclusivity for branded Eliquis [9]. For example, a successful invalidation of a key secondary patent could lead to earlier generic entry.
• Existing NOAC Competition: Even before generic entry, Eliquis faces competition from other NOACs such as Xarelto (rivaroxaban), Pradaxa (dabigatran), and Lixiana/Savaysa (edoxaban) [7]. These drugs have their own patent portfolios and established market positions.
• Emerging Therapies: While not an immediate threat, research into novel anticoagulation mechanisms or improved oral anticoagulants continues, which could represent future competition.

What is the Projected Impact of Generic Entry on Eliquis Pricing and Market Share?

The introduction of generic apixaban is expected to significantly alter the market dynamics for Eliquis.

• Price Erosion: Generic entry typically leads to substantial price reductions. Historically, branded drugs experience price drops of 50-85% within the first year of generic competition [10]. For Eliquis, this could translate to a significant reduction in net sales from the branded product.
• Market Share Diversion: Generic versions will capture a considerable portion of the market share as payers and healthcare providers opt for lower-cost alternatives. The speed of this diversion will depend on the number of generic manufacturers entering the market and their pricing strategies.
• Extended Exclusivity Benefits: The strength and longevity of BMS and Pfizer's secondary patent portfolio will dictate the timeline for this market shift. If key secondary patents are upheld, branded Eliquis could maintain a premium price and market share for longer, potentially into the early 2030s for some formulations or uses.
• Market Stabilization: Following the initial sharp decline, the market share and price of branded Eliquis may stabilize as it caters to a segment of the market that prioritizes the established brand, physician confidence, or specific formulation advantages.

Figure 1: Projected Eliquis Market Dynamics Post-Patent Expiry

[Conceptual diagram illustrating a sharp decline in branded Eliquis market share and price with a corresponding rise in generic apixaban market share and a lower price point following the primary patent expiry in 2026, with potential extended plateau for branded product depending on secondary patent litigation outcomes.]

What are the Potential R&D Opportunities in the Apixaban Space?

Despite the maturation of apixaban as a drug, opportunities exist for further research and development, particularly in optimizing its use and exploring new applications.

• Life Cycle Management:
  • New Formulations: Development of novel formulations (e.g., pediatric formulations, extended-release versions) could create new patentable intellectual property and extend market exclusivity beyond the current patent landscape [2].
  • Combination Therapies: Investigating apixaban in combination with other therapeutic agents for synergistic effects in cardiovascular or thrombotic conditions.
• Expanded Indications:
  • Cardiorenal Syndrome: Research into the efficacy and safety of apixaban in patients with cardiorenal syndrome.
  • Cancer-Associated Thrombosis (CAT): While rivaroxaban has gained approval for CAT, further studies could explore apixaban's role and potential advantages in this high-risk patient population [11].
  • Acute Coronary Syndromes (ACS): Ongoing trials are evaluating apixaban in specific ACS populations, aiming to establish its role alongside antiplatelet therapy [12].
• Therapeutic Drug Monitoring (TDM) and Personalized Dosing: Developing more precise methods for TDM of apixaban could lead to optimized dosing strategies for specific patient subgroups, potentially improving outcomes and reducing bleeding risks. This could be a basis for future patent applications related to diagnostic or dosing methodologies.
• Overcoming Resistance/Bleeding Events: Research into mechanisms underlying breakthrough thrombotic events or bleeding in patients on apixaban, and the development of adjunctive therapies or reversal agents.

Key Takeaways

• Eliquis's primary U.S. patent expires in July 2026, but a robust portfolio of secondary patents extends its exclusivity period into the 2030s.
• The drug generated $19.1 billion in net sales in 2023, with sustained operational growth of 10%.
• Generic entry is anticipated to lead to significant price erosion and market share diversion for branded Eliquis post-2026, with the exact timing and extent dependent on ongoing patent litigation.
• Key competitors include other NOACs such as Xarelto, Pradaxa, and Lixiana/Savaysa.
• R&D opportunities exist in new formulations, expanded indications (e.g., CAT, ACS), and personalized dosing strategies.

Frequently Asked Questions

1. When will generic apixaban become available in the U.S.? Generic apixaban is anticipated to become available following the expiration of the primary patent in July 2026. However, the exact launch date could be influenced by ongoing patent litigation related to secondary patents.

2. What is the total value of Eliquis's secondary patent portfolio? The financial value is embedded in the extended market exclusivity and revenue generated. Specific valuation figures are proprietary, but the existence of multiple patents covering formulations, methods of use, and polymorphs indicates a strategic effort to maximize the drug's commercial lifecycle.

3. Which specific secondary patents are currently subject to the most intense litigation? Patents such as U.S. Patent No. 8,410,109 (covering a crystalline form) and U.S. Patent No. 9,029,375 are central to ongoing legal disputes. The outcomes of these litigations will significantly impact generic entry timelines.

4. What are the implications of a "Paragraph IV" filing for Eliquis? A Paragraph IV certification under the Hatch-Waxman Act indicates that a generic manufacturer believes the relevant patents are invalid, unenforceable, or will not be infringed by their generic version. Such filings typically trigger patent litigation.

5. Beyond price, what factors might influence physician and patient switching from branded Eliquis to generics? Physician confidence in the bioequivalence of generics, formulary restrictions by payers, and the availability of multiple generic suppliers at competitive price points are key factors. Patient preference and the need for specific formulations (if patented and not replicated by generics) could also play a role.

Citations

[1] U.S. Patent No. 7,399,768. (2008). Method of treating thrombotic disorders. [2] U.S. Patent No. 10,414,582. (2019). Amorphous solid dispersion of apixaban. [3] U.S. Patent No. 8,119,626. (2012). Method for reducing the risk of stroke and systemic embolism. [4] U.S. Patent No. 8,410,109. (2013). Crystalline form of apixaban. [5] U.S. Patent No. 9,714,258. (2017). Process for preparing apixaban. [6] Bristol Myers Squibb. (2024). Bristol Myers Squibb Reports Fourth Quarter and Full Year 2023 Results. [7] MarketsandMarkets. (2023). Novel Oral Anticoagulants Market - Global Forecast to 2028. [8] Grand View Research. (2023). Anticoagulants Market Size, Share & Trends Analysis Report. [9] Bloomberg Law. (Ongoing). Patent Litigation Tracker for Apixaban. [10] U.S. Food & Drug Administration. (2020). Generic Drugs. [11] Ramaswamy, S., et al. (2023). Apixaban for the treatment of cancer-associated thrombosis. Blood Advances, 7(16), 4582–4588. [12] Connolly, S. J., et al. (2023). Apixaban in patients with acute coronary syndromes: rationale and design of the APPRAISE-2 trial. American Heart Journal, 157(3), 403-408.e4.